Convention at Congress Center Zoo Leipzig, March 21-23
The future of medical technology has finally come home: we are looking forward to present our ACG technology at XPOMET Leipzig. Both 22nd and 23rd of March will see Sonovum speakers with ACG technology insights. The convention's organisation committee calls it an "hommage to technology, progress and future thinking in medicine. The convention is hosted at Congres Center Zoo Leipzig; you will find us at UG, booth 162 in DX-2 "Medical Diagnostix". Please refer to the convention's website for more info:
We are very much looking forward to welcoming you at our stand!
We are specialists in Brain Monitoring. Currently, we are the only company worldwide to be able to non-invasively monitor minuscule changes in the cellular and molecular structure of brain tissue. With our newly developed technology, Acoustocerebrography (ACG), we can monitor these changes in acute settings as well as Permanent Monitoring settings.
We are thus able to detect events previously undetected by traditional methods. Furthermore, ACG allows for a detection of these events while they occur, as it monitors brain tissue continuously. This enables us to determine indicators for pathologic conditions that so far even specialists have been unable to discover.
Clinical trials with our Acoustocerebrographs have shown, for example, that ACG is able to identify and classify strokes as well as pre-qualify White Matter Lesions (WML).
What is more, they support the conclusion that other pathologic changes will also be visible; such as Septicemia, Dementia or Intracranial Pressure (ICP). Further hypotheses are being researched in cooperation with selected University Medical Centers.
Our founders are able to build on 20 years of research and application experience in Molecular Acoustics. We are headquartered at BIOCUBE center of competence, Old Trade Fair, Leipzig.
This medical technology company was founded in 1989 by the Polish Academy of Sciences and a group of researchers from the Institute of Fundamental Technological Research. Sonomed researches, develops and constructs highly specialized accessories for medical ultrasound equipment. Sonovum benefits from the technological know-how of Sonomed through intensive cooperation.
exceet Electronics is a full-service provider for the development and production of complex electronic components, modules and systems in the industrial and medical fields. The company is part of the Swiss technology group, exceet Group. Specialists from exceet supported Sonovum AG in the development of their electronics and in the mass production of ACG machines for mobile stroke diagnosis.
E3 Technology offers research and development services for analogue and digital technologies. The focus of the company, which has its headquarters in Warsaw, is on tailor-made technological solutions for military, marine and industrial applications, in particular in the fields of power electronics and high-precision measurement and control technology. E3 Technology supports the entire product development process - from consulting and design to implementation of systems. In the field of measurement technology, the company offers system solutions for controlling medical and industrial processes.
Concept Design Pilz is involved with the industrial design of products, mainly in the fields of medicine and energy technology, as well as consumer goods. The company, based in Stuttgart, offers unparalleled services in product design - from concept, all the way through the development of prototypes to production-ready devices. For Sonovum AG’s ACG devices, the Swabian company has developed a design concept for the output medium that displays the data measured.
The Fraunhofer Institute for Cell Therapy and Immunology (IZI) investigates and develops solutions to specific problems at the interfaces between medicine, life sciences and engineering. Within this framework, the institute contracts to do research for biotechnological, pharmaceutical and medical device companies, clinics, diagnostics laboratories and research institutions. Within the business fields of cell therapy, diagnostics and biobanks, the Institute develops, optimizes and validates processes, materials and products. From the very beginning, Sonovum AG has synergised competencies with the Fraunhofer IZI for basic research and development work and therefore has ideal research conditions for further development of its technology.
The Saxon Biotechnology / Life Sciences cluster is led by biosaxony eV. There are currently 111 biosaxony members, made up of companies, research institutes, academic institutions, individuals and stakeholders in the sector. The cluster’s objectives include initiating projects between companies and scientists, the provision and procurement of consulting and other services, the representation, bundling and strengthening of existing know-how and regional expertise in Saxony, the exploitation of synergies for the further development of key technology and cross-industry biotechnology and links to neighboring areas such as health, food, energy and engineering and materials science. The network provides Sonovum AG with valuable contact to industry members and research and development institutions.
BIO CITY in Leipzig is an incubator for modern technology and business in the field of biotechnology and biomedicine. Start-ups and young companies in particular can find individual laboratory and office space here. Since it opened in the spring of 2003, many companies have been sharing, researching and working together with six biotechnology-related professorships and non-university institutions, in a space of approximately 20,000 square meters.Sonovum AG has found the ideal business location in Bio City, as it offers the best conditions for successful research and development work.
The German Stroke Foundation, headquartered in Gütersloh, is working with numerous partners on the development and implementation of comprehensive health care concepts for stroke patients, along the entire health care chain - from prevention and health promotion, through emergency management and acute care to rehabilitation and aftercare. Their objectives are, first and foremost, education and improvement of diagnostic and therapeutic options. The Foundation sees itself as an extensive base of information about strokes and as the driving force in education and prevention.
Forum MedTech Pharma is the largest Health Network of its kind in Germany and Europe. It fosters cooperation, enhances networking and helps distributing information about the newest trends and innovations. The forum offers its knowledge in numerous conventions, workshops, congresses and seminars. Being one of its 600 members from Science, Industry and Health, Sonovum benefits greatly from this know how transfer between Medicine, MedTech, Pharma and associated areas.
As a trade association, BVMed promotes and represents the combined interests of the medical technology industry and trade companies. The association offers its members a platform for a constructive dialog and exchange of views in various working groups. Through public relations work and by participation in the development of laws, guidelines and standards, BVMed represents the concerns of its member companies to policy makers and the public in general.
Health Tech Cluster Switzerland is a pan-European business network open for companies and organisations within the Life Sciences sector. Contrary to most other networks, HTC prides itself with supporting a broad and somewhat diverse members' structure; companies can synergize as well as compete on each other's know-how, products and services, fostering knowledge transfer on an international level. HTC's management has been around Life Sciences for a substantial number of years and provides its members with studies and reports on industry's latest.
At the Innovation Forum "Quantitative Ultrasound in Medicine" (QSonoMed), the first informal network was initiated in 2015. This network includes companies, research institutes and medical users involved in the field of non-ultrasound imaging methods. These methods allow diagnostically relevant physical parameters of biological tissues and fluids to be non-invasively determined.
The ultimate goal of all the involved network partners has always been to drive the development of medical technology in this field and thus to encourage regional and national growth impetus. What began as a conference has developed into a professional operating network. The ultrasound research centre, as an initiator of the Innovation Forum, is committed to taking that step. Here, Sonovum AG finds like-minded people from this specific field of medical technology to exchange ideas and engage in cooperative projects.
RehaReform aims to jointly develop applications and devices that are both inexpensive and need-based for use in rehabilitation and orthopedics. In order to achieve this goal, close cooperation with hospitals, health insurance providers and rehab as well as care services is key. For exchange, ist 12 member companies and 3 research institutions locally meet on a regular basis.
Telephone: +49 341 39299-510
Sales tax identification number according to §27 German Sales Tax Law: DE281226472
Commercial Registered - Leipzig Court: HRB 27913
Responsible according to § 55 section 2 RStV and TMG: Bertram König
CEO: Bertram König
CTO: Miroslaw Wrobel
Chairman of the Supervisory Board: Bernd Minning
The contents of this website were written with due diligence and by the author’s best knowledge. We can be held liable only by general laws, especially for our own contents acc. § 7 TMG (German law on tele-media) and for external contents acc. §§ 8 – 10 TMG. As a Provider of tele-media we can be held liable for external contents only once we have knowledge of a concrete infringement of law. We reserve the right to change or delete contents of this webpage which are not subject to any contractual obligation.
The equipment featured on our website is not available for either commercial or private use and is therefore not on the open market. These devices are for use in ongoing research projects, and are used exclusively in clinical trials and preliminary studies for the purposes of data collection and validation.
The information published on our website cannot and should not replace a medical consultation and represents only the level of knowledge as of date of publication.Links on external Websites
Contents of external websites on which we are linking direct or indirect are beyond our responsibility and are not adopted as our own content. When the links were published, we didn’t have knowledge of any illegal activities or contents on these websites. Since we do not have any control on the contents of these websites, we distance ourselves from all contents of all linked websites, which were updated after the setting of the links. For all contents and especially damages, resulting of the use of the linked websites, only the provider of these linked websites can be held liable. If we receive knowledge of illegal contents on these linked websites, we will delete the according links.
All content of this website, especially texts, pictures, images, graphical presentations, music, trademarks, brands and so forth, are subject to copyright laws. The use, reproduction and so on are subject to the individual rights of the respective owner of the copyright or administrator of these rights. If you want to use such content, please let us know and we will establish contact with the respective owner/administrator.
The provider and controller within the meaning of the Telemedia Act (TMG) and the Federal Data Protection Act (BDSG) is
Explanations of the technical terms can be found in the GDPR Article 4.3. Use of the website
To analyse user behaviour we use "Google Analytics", a web analysis service provided by
1600 Amphitheatre Parkway
Mountain View, CA 94043
Google Analytics uses so-called "cookies", which are text files that enable analysis of the use of the website. These cookies are stored on your computer.
The information collected includes the browser type, the version of the browser, the operating system used, the referrer URL (the previously visited website), the IP address and the time of the server request. Your IP address is masked by the option "anonymizeIP", so that your data is made anonymous. This data is transmitted to a Google server in the USA. On our behalf, Google uses this data to evaluate usage behaviour on the website and to create activity reports.4.2 Objection
You can prevent Google from collecting and processing the data by clicking on the following link and downloading an add-on to deactivate Google Analyticshttps://tools.google.com/dlpage/gaoptout?hl=de 5. Newsletter5.1 Contents of the newsletter
Our newsletter informs you about the current press releases and events of Sonovum AG.5.2 Registration data
To subscribe to the newsletter, we need your email address and first and last name. The email address is required to send you the newsletter, while your first and last name are used to personalise the newsletter. Specifying the company is optional, but also serves to personalise and adapt the newsletter to specific interests.5.3 Double-Opt-In
To receive our newsletter, double confirmation – a so-called double opt-in – is necessary. This means that you will receive an email after registration, from which you must confirm your registration again. Both registrations are recorded, as we have to provide proof of them due to legal requirements.5.4 Use of MailChimp
Our newsletter is organised by "MailChimp", a mailing platform for newsletters from the US provider
The Rocket Science Group, LLC
675 Ponce de Leon Ave NE
Atlanta, GA 30308 USA.
All data collected during registration is stored on servers in the USA. MailChimp sends the newsletters and evaluates them on our behalf. According to its own information, MailChimp also uses its data to optimise its own services, or for economic purposes to determine the countries the recipients come from. MailChimp does not use your personal data to write to you, nor does it pass it on to third parties.
You can revoke your consent at any time and without giving reasons. This causes a deletion of any of your personal data used by us or MailChimp. At the same time, your consent to the processing of your data by statistical analysis and to the dispatch of the newsletter will expire.6. Rights of the data subject6.1 Right to information
According to Art. 15 GDPR, you have the right to know if and which of your personal data we store or process. To exercise this right, please contact the data protection officer in writing. You will find the contact details below.6.2 Right to correction and deletion
If we have stored personal data about you, you have the right to its correction or completion in accordance with Art. 16 GDPR, and the right to its deletion in accordance with Art. 16 GDPR. If you assert the right of deletion, your personal data will be deleted immediately, unless there is another reason under Art. 6 GDPR to permit its processing. To exercise this right, please contact our data protection officer, whose contact details can be found below.6.3 Right to limitation of processing
If we process your personal data, you have the right to restriction of the processing according to Art. 18 GDPR. You can exercise this right by contacting our data protection officer, whose contact details can be found below.6.4 Right to data transferability
If we have stored your personal data, you have the right to receive it from us in a machine-readable format, or to transfer it to another person responsible in accordance with Art. 20 GDPR. To exercise this right, please contact our data protection officer, whose contact details can be found below.7. Change in the regulations
We reserve the right to amend this data protection declaration for legal or technical reasons. Therefore please note the version which applies at any specific time.8. Contact data of our data protection officer
If required, you can contact our data protection officer at the following address:
There are no FAQ entries at this time
There are no Glossary entries at this time